Table 2.
Baseline Demographics for the Study of Patients, N (%)
| Variable | All patients (N = 98) |
|
|---|---|---|
| N | % | |
| Age, y | ||
| <65 | 26 | 27 |
| ≥65 | 72 | 73 |
| Sex | ||
| Female | 8 | 8 |
| Male | 90 | 92 |
| Histologic subtype | ||
| Epithelioid | 74 | 76 |
| Sarcomatoid | 8 | 8 |
| Biphasic | 8 | 8 |
| Missing | 8 | 8 |
| ECOG PS | ||
| 0 | 21 | 21 |
| 1 | 55 | 56 |
| 2 | 18 | 18 |
| 3 | 2 | 2 |
| Missing | 2 | 2 |
| Location of Mesothelioma | ||
| Pleural | 95 | 97 |
| Peritoneal | 3 | 3 |
| EPP | ||
| Yes | 8 | 8 |
| No | 89 | 91 |
| Missing | 1 | 1 |
| Pembrolizumab line of therapy | ||
| First line | 4 | 4 |
| Second line | 63 | 64 |
| Third line | 21 | 21 |
| More than third line | 10 | 10 |
| Cycles of pembrolizumab | ||
| Median | 6 | |
| Range | 1–35 | |
| Dexamethasone prepembrolizumab | ||
| Yes | 12 | 12 |
| No | 85 | 87 |
| Missing | 1 | 1 |
| Dexamethasone dose, mg (n = 9) | ||
| Median | 4 | |
| Range | 1.0–7.5 | |
| irAEs | ||
| No | 71 | 72 |
| Yes | 26 | 27 |
| Missing | 1 | 1 |
| Postpembrolizumab treatment | ||
| Yes | 13 | 13 |
| No | 85 | 87 |
| Blood counts | ||
| NLR | ||
| <5 | 56 | 57 |
| ≥5 | 36 | 37 |
| Missing | 6 | 6 |
| Baseline white blood cell count (×109/liter) | ||
| <8.3 | 52 | 53 |
| ≥8.3 | 40 | 41 |
| Missing | 6 | 6 |
| Baseline platelet count (×109/liter) | ||
| ≤400 | 65 | 66 |
| >400 | 27 | 28 |
| Missing | 6 | 6 |
| Hemoglobin difference, g/liter | ||
| <10 | 8 | 8 |
| ≥10 | 84 | 86 |
| Missing | 6 | 6 |
| Eosinophils count | ||
| Low (<0.02) | 16 | 16 |
| Normal (0.02–0.5) | 70 | 71 |
| High (>0.5) | 5 | 5 |
| Missing | 7 | 7 |
| Albumin count, g/liter | ||
| Low (<26) | 6 | 6 |
| Normal (26–42) | 78 | 80 |
| High (>42) | 8 | 8 |
| Missing | 6 | 6 |
| Biomarkers | ||
| PD-L1 TPS score, % | ||
| <1 | 45 | 46 |
| ≥1 | 31 | 32 |
| Missing | 22 | 22 |
| BAP1 | ||
| Loss | 35 | 36 |
| Retained | 40 | 41 |
| Missing | 23 | 23 |
| CD3+ TILs tumor, % | ||
| <5 | 40 | 41 |
| ≥5 | 36 | 37 |
| Missing | 22 | 22 |
| CD3+ TILs stroma, % | ||
| <5 | 7 | 7 |
| ≥5 | 64 | 65 |
| Missing | 27 | 28 |
Note: BAP1, BRCA1 associated protein-1; irAE, immune-related adverse event; TIL, tumor-infiltrating lymphocyte; ECOG PS, Eastern Cooperative Oncology Group performance status; EPP, extrapleural pneumonectomy; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed cell death-ligand 1; TPS, tumor proportion score.